Pulmonology

Rifapentine-based regimen may allow for shorter course in tuberculosis

Treatment with rifapentine-based regimen for 4 months was found to be noninferior to the standard 6-month regimen in patients with tuberculosis, according to a study. In this open-label, phase 3, randomized, controlled trial, 2234 patients with newly diagnosed pulmonary tuberculosis were assessed for the primary outcome of survival free of...